ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 15, 2017 11:15 JST
Source:
Alset International Ltd
First-Year Performance of Global Systematic Multi-Strategy Fund
SINGAPORE, Jun 15, 2017 - (ACN Newswire) - The Board of Directors of Singapore eDevelopment Ltd ("SeD" or "the Group") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation. The net returns are calculated by its fund administrator, Maples Fund Services.
Launched on 1 June 2016, the GSMS Fund adopts an "all-weather" strategy that seeks to produce consistent risk-adjusted returns regardless of market volatility. The GSMS Fund employs a systematic approach focusing on liquid exchange traded securities that are diversified across asset classes, geographical regions and time-frames.
HFAM intends to allow investors the option to receive 100% of the net profits (after all fees) on an annual basis or to reinvest all profits back into the fund. HFAM also intends to offer the GSMS Fund to global fund of funds.
HFAM is a registered fund management company regulated by the Monetary Authority of Singapore. As at the date of this announcement, HFAM manages two (2) live funds, namely, the GSMS Fund and Global Opportunity Fund. As announced by the Company on 15 May 2017, HFAM also intends to manage two (2) additional funds, namely, Global Property Development Fund and Global High Yield Income Fund. The Company will make subsequent announcements to update its shareholders when there are material updates as may be necessary or appropriate.
The acquisition of HFAM is part of the Group's efforts to develop new revenue streams and is in line with the Group's pursuit of providing capital services and creating opportunities to accelerate SeD's corporate recovery.
SeD website: www.sed.com.sg
HFAM website: www.hf-asset.com
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.
Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01, Royal Group Building
Singapore 048693
Mr Ian Lau
E:
ianlau@wer1.net
T: +65 6737 4844
Source: Alset International Ltd
Sectors: Funds & Equities
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 00:53 JST
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 30, 2025 00:33 JST
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 00:26 JST
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 00:18 JST
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 30, 2025 00:00 JST
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 29, 2025 23:55 JST
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 29, 2025 23:50 JST
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 29, 2025 23:39 JST
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 29, 2025 23:22 JST
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 29, 2025 23:00 JST
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center
Oct 29, 2025 11:00 JST
Gannon & Scott has signed a definitive agreement to join Metalor Technologies
Oct 29, 2025 04:00 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Oct 29, 2025 00:30 JST
Mitsubishi Heavy Industries Machinery Systems to Exhibit at Japan Mobility Show 2025
Oct 29, 2025 00:00 JST
Fujitsu AI transforms regional healthcare in Iki city
Oct 28, 2025 23:24 JST
Hitachi announces initiatives aligned with Japan - U.S. strategic investments
Oct 28, 2025 22:34 JST
NEC Achieves Cisco Gold Provider Status, Strengthening Global Strategic Partnership in the AI era
Oct 28, 2025 22:09 JST
Honda to Invest in OMC Power, which will Launch Leasing Business for Uninterruptible Power Supply Device in India
Oct 27, 2025 21:20 JST
Fujitsu, Logistics Knight Japan, and Isuzu Motors launch joint pilot project to build pharmaceutical logistics platform aiming for stable supply
Oct 27, 2025 17:31 JST
JCB Explores Opportunities to Expand Card Acceptance through Partnership with STC Bank
Oct 27, 2025 15:00 JST
More Latest Release >>
Related Release
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
More Press release >>